BioSpace News Archive

Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics, today announced multiple data presentations at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting.

Vera Therapeutics, Inc. (Nasdaq: VERA), , today announced that interim data from the Phase 2 trial of MAU868 versus placebo to treat BK Virus (BKV) in kidney transplant patients will be delivered in a late-breaking oral presentation at the American Transplant Congress (ATC) 2022 in Boston, Massachusetts.

GC Biopharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 31 March 2022.

Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2022 and business highlights.

Senti Bio, a leading gene circuit company, today announced the acceptance of four abstracts for presentation at upcoming scientific conferences.

SeaSpine Holdings Corporation announced the full commercial launch of OsteoTorrent and OsteoTorrent C, both of which are new Accell DBM Putties packaged and sterilized in a dry state and designed to further improve osteoinductive potential and shelf-life, while allowing surgeons to reconstitute with saline, blood or bone marrow aspirate.

ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2022 financial results and provided a corporate update.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), today announced that it will provide a corporate update and report financial results for the first quarter 2022 on Monday, May 9, 2022, after the U.S. financial markets close.

Veracyte, Inc. (Nasdaq: VCYT) announced today that an updated clinical practice guideline highlights the role of the Envisia Genomic Classifier in the diagnosis of idiopathic pulmonary fibrosis (IPF).

Genenta Science announces that preliminary findings from its Phase 1/2a of Temferon™ in the treatment of patients with glioblastoma multiforme patients who have an unmethylated MGMT gene promoter provide initial evidence of Temferon’s potential for modulating the tumor microenvironment as well as details of Temferon’s continuing positive safety profile and signals of biological activity.